Brief: Helix Biopharma Corp - L-Dos47 Phase Ii Randomized Study Advances To Second Cohort
01/05/2019 13:25
May 1 (Reuters) - Helix Biopharma Corp HBP.TO :
* HELIX BIOPHARMA CORP - L-DOS47 PHASE II RANDOMIZED STUDY
ADVANCES TO SECOND COHORT
* HELIX BIOPHARMA CORP - NO SERIOUS ADVERSE EVENTS OR DOSE
LIMITING TOXICITIES WERE OBSERVED FROM FIRST DOSING COHORT OF
LDOS003 STUDY
Source text for Eikon: ID:nGNX5wMzY6
Further company coverage: HBP.TO
((Briefs@thomsonreuters.com;))
Recent news on Helix Biopharma
See all newsBrief: Helix Biopharma Reports Q3 Loss Per Share C$0.02
Brief: Helix Biopharma Intends To File Interim Consolidated Financial Statements By July 30
Brief: Helix Biopharma To Divest Remaining Ownership Of Polish Subsidiary
Brief: Helix Biopharma Says Expects To File Interim Disclosure Documents By July 30, 2020
Brief: Helix Biopharma Says L-Dos47 Phase I Lung Cancer Trial Data To Be Released At Asco 2020